Macter International Launches Hepanox Pre-Filled Syringe
Macter International Limited has announced the successful launch of Hepanox (Enoxaparin Sodium) Pre-filled Syringe (PFS), marking a new development in the company’s biopharmaceuticals portfolio.
In a material information notice dated September 25, 2026, the company informed the Pakistan Stock Exchange Limited that Hepanox PFS has been launched as part of its efforts to strengthen its presence in the anticoagulant therapeutic segment.
Hepanox PFS contains Enoxaparin Sodium, a low molecular weight heparin (LMWH) anticoagulant. The pre-filled syringe format represents an addition to Macter International’s biopharmaceutical product offerings.
According to the company, the launch is an important milestone for its biopharmaceuticals portfolio and supports its efforts to expand its presence in the anticoagulant market. Macter also stated that the development is aligned with its longer-term growth strategy and its focus on addressing evolving healthcare needs.
The announcement was issued in compliance with Sections 96 and 131 of the Securities Act, 2015, as well as Clause 5.6.1 of the Rule Book of the Pakistan Stock Exchange. The notice was signed by Asif Javed, Company Secretary of Macter International Limited.
The launch adds another product to Macter’s biopharmaceutical portfolio and reflects the company’s stated strategy of expanding its therapeutic offerings. Further details regarding the commercial performance, sales outlook or financial impact of Hepanox were not provided in the material information notice.
